The health care industry is taking a stand against the maker of EpiPen
The health care industry is taking a stand against the maker of EpiPen
As we all know, the maker of EpiPen, Mylan, has engaged in price gouging. But this week, the larger health care industry sent a strong message that they are not going to stand for it. On Wednesday, Cigna announced it would only cover the generic version of EpiPen. On Thursday, CVS announced a deal with an EpiPen competitor that could hurt Mylan’s generic sales. It’s a strange and unusual kind of pushback. The kind we rarely see in the health care industry.
Click the above audio player to hear the full story.
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.
